The US Food and Drug Administration (FDA) is continuing a fast pace of enforcement against allegedly misleading prescription‑drug advertising, issuing 18 enforcement letters in the first half of 2026 alone – already exceeding the total number released during the final three years of the Biden administration.
While last year saw a dramatic